Study ID: ECOG E1411
Description:

Intergroup Randomized PhaseII Four Arm Study In Patients >/= 60 with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A=Rituximab+Bendamustine Followed by Rituximab Consolidation (RB->R); Arm B=Rituximab+Bendamustine+Bortezomib Followed by Rituximab Consolidation (RBV->R);Arm C=Rituximab+Bendamustine Followed by Lenalidomide+Rituximab Consolidation (RB->LR), or Arm D= Rituximab+Bendamustine+Bortezomib Followed by Lenalidomide and Rituximab Consolidation (RBV->LR).

Location:
Fargo Region,Bemidji Clinic
Principal Investigator:
Preston Steen MD
Disease:
Hematologic, Other
Stage:
Phase II

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list